HedgeRoll - Value Investing and After Tax Returns
  • HedgeRoll
  • Contact
  • Research

hedgeroll

In Search of After-Tax returns

Salix Investors Looking for a BUYOUT Should be cautious; More accounting problems ahead

11/22/2014

0 Comments

 
Investors in Salix Pharmaceuticals were treated to some unpleasant news on November 6th. The company announced they had misrepresented key drug inventories, and the CFO resigned. SLXP traded down -34% the next day and -46% from its September highs.  I believe more accounting issues will be uncovered by the audit committee.
The company has all but admitted that it was channel stuffing, a practice used to inflate earnings, as discussed in my last post Was the Salix Blowup Predictable? This earnings inflating trick increased wholesaler inventories to levels way beyond their stated target, and much higher than industry norms.
Since the sell off, shares have rebounded. Investors are speculating either there is only one cockroach in Salix's kitchen, or it is still a takeover candidate despite the accounting issues. Indeed this company has a valuable GI drug franchise, and management with a credibility issue. 

The setup seems ripe for M&A activity. Further bolstering this line of thinking is Salix was previously a target of both Actavis (ACT) and Allergan (AGN), but talks fell apart during due diligence around inventories.  However, an audit committee composed of independent directors have been convened, and  I believe that the audit committee will uncover more accounting problems. For those who still wish to wager on a Salix acquisition, I have outlined a strategy at the end of this article.

One of the most useful tools for detecting earning manipulation is the Beneish M-Score. Developed by Dr. Messod  Beneish of the Kelly School of Business, and detailed in The Detection of Earnings Manipulation. The M-Score uses forensic accounting principles to produce a "Probability of Manipulation" or PMAN for any given company  by comparing two 12 month periods.

I was first introduced to the Beneish M-Score in Quantitative Value: A Practitioner's Guide to Automating Intelligent Investment and Eliminating Behavioral Errors. This book is excellent and I wholeheartedly recommend it.

In the book, the authors relate a story about an MBA team from Cornell which used the M-Score to give a "sell" recommend on Enron, a full year before it's collapse.

So what does the M-Score and its Probability of Manipulation say about Salix Pharmaceuticals? 
Picture
"Never is there just one cockroach in the kitchen" - Warren Buffett

In Quantitative Value,  they noted the M-Score gave Enron a 30.5% PMAN.  For 1Q14 Salix has a 50.8% PMAN. That is what I call a red flag. Even it's 2Q14 score of 5.8% is high enough to be considered a weak signal.

Let's do some more digging; what is the M-Score recognizing in Salix to give it such a high PMAN?

The Beneish M-Score is a multifactor model with eight variables, each being a hot spot of earning manipulating activity. The eight variables are below:

  1. DSRI - Days' sales in receivable index: Detect revenue inflation activity such a channel stuffing.
  2. GMI - Gross margin index: Firms with declining margins may be more likely to manipulate earnings.
  3. AQI - Asset quality index: Rising intangible assets may point to deferred costs, boosting  earnings.
  4. SGI - Sales growth index: High growth firms have incentives to manipulate earnings when they fall short.
  5. DEPI - Depreciation index: Slower deprecation can artificially boost earnings.
  6. SGAI - Sales and general and administrative expenses index: Can point out overcompensated execs, who have been associated with earning manipulation.
  7. LVGI - Leverage index: Firms with increasing leverage are incentivized to manipulate earnings when faced with a shortfall due to debt covenants.
  8. TATA - Total accruals to total assets: Firms with higher accruals are likely to be earning manipulators.

Lets look at the table below to see how Salix scored on these variables compared to peers:
Picture
Picture
Based on the table above, and information the company has shared, I expect the following outcomes from the audit committee:
  • Salix has been manipulating their expenses and will have to restate at least one quarters earnings. The method used is either intangibles to defer costs (AQI), or hiding something in accruals (TATA).
  • The lower margins will be disclosed to be part of the channel stuffing (GMI), as will the higher accounts payable (DSRI), as discussed previously.
  • Salix will not restate revenues, but may lower revenue guidance once the full impact of channel stuffing is known.

In short, I believe investors should be very cautious on owning Salix shares until the audit committee releases their findings.  An approach for those determined to make a bet on a Salix acquisition should consider a small starter position, with the intention to use the negative headlines from the audit committee as an opportunity to buy on weakness.

Sign up for my emails. 

I will only reach out when I have something interesting to share.
Email Marketing You Can Trust
Picture
Disclosure:

I have no position in Salix Pharmaceutics as of this writing,  but may establish one in the future.

Geek Notes:
  1. All my data is from Ycharts.com, as is the Beneish M-Score calculation.
  2. Peer Group: US Listed Biotechnology, Pharmaceutical, and Generic/Specialty Drugs Companies with Enterprise Value greater than $3.0B, annual Revenues greater than $100M, and annual EBITDA greater than $0. After removing any companies with incomplete data, 38 remained.
0 Comments

Was the Salix blowUp Predictable?

11/10/2014

0 Comments

 
Could the blowup at Salix Pharmaceuticals been seen in advance? This is a Monday morning quarterback look at the financials  in search for a tell.  
Picture
Investors in the pharma and biotech space are accustomed to certain risks; Clinical, regulatory, and commercialization risk are at the top of healthcare investors mind. 

Accounting shenanigans are not the sort of thing that keeps healthcare investors up at night. This is why the channel stuffing scandal at Salix Pharmaceutical has been so shocking, despite Bristol-Myers and Medicis having paid to settle channel stuffing allegations in the past. 

With Q3 2014 earnings, Salix Pharmaceuticals announced that key product inventory levels at distributors are elevated to nine months, well beyond the levels previously disclosed.  Adam C. Derbyshire, former Chief Financial Officer, has stepped down, and an independent audit committee has been convened to figure out what exactly went wrong.

The problem with channel stuffing (besides being misleading) is it steals sales from future periods. This approach could be used by management in a one-off scenario, with a low risk of being found out. However human nature leads them back to the same well until it is dry. 

There are legitimate reasons for distributors to allow inventories to build. For example, expected price increases, supply issues, and rising demand. While these all could play a part, management has all but admitted to channel stuffing. Below is a great graphic on the pharma supply chain from ContracIQ.
Picture
Why would distributors accept more inventory than needed? Because the company incentivizes them to stock up, so that the company may meet their sales targets. This is typically done through special financing arrangements. Extended payment terms, and product discounts are typical.  

A channel stuffing  company would show an unusual rises in accounts receivable due to the extended payment terms, and timing. These deals typically occur near the end of the quarter, when management knows it won't hit sales targets on their own. Also look for some impact on gross margins, due to discounts offered to incentivize distributors.

I recommend What's Behind the Numbers?: A Guide to Exposing Financial Chicanery and Avoiding Huge Losses in Your Portfolio. Authored by a short bias fund manager, it exposes many of the accounting tricks companies pull, such as channel stuffing.

When evaluating receivables, you have to look at it relative to revenues, as a quickly growing firm would naturally have rising receivables. Furthermore, you have to look at the trend in receivables. Quarterly Year over Year comparisons smooth out seasonality, and is the preferred metric.

There  few reasons AR can grow faster than sales:
  • Processing problems in the AR department 
  • Customers cannot or will not pay 
  • Channel Stuffing
Picture
The huge spike in Q1 2014 is suspect. Salix closed the Santarus deal on January 2, 2014. Could it be related the the Santarus acquisition? 

Santarus had $43.5M in receivables in Q3 2013. Salix receivables rose from $146.9M in Q4 2013 to  whopping $438.5M one quarter later Q1 2014. So that doesn't explain it. If there is a smoking gun, I would say Quarter Y/Y receivables growth is it.

These types of issues apparently scared off Allergan.

 Furthermore, I haven't seen anything in the earnings calls or filings that explain the dramatic rise. Not that I would believe it now, coming from a disgraced CFO.

The overall level of receivables were also very high. Among a peer group of companies I created for this research, Days Sales Outstanding for Salix was the 3rd highest.

What about that other factor I mentioned,  gross margins?
Picture
Margins have been impacted too. On this item, management had an explanation, however I would not be surprised if the audit committee ends up questioning this statement:
“The lower gross margin in the second quarter of 2014 was due primarily to the inclusion of sales of GLUMETZA, which carried lower gross margins than our other products.” 
Adam C. Derbyshire - (former) Chief Financial Officer,  Q2 2014 earnings call
I find it particularly telling that in the Q1 2014 and Q2 2014 earnings call transcript, the word "discount" never appears. However, on the Q4 2014 call , the interim CFO had this to say:
 "As we said, the shortfall is because of our prescription growth on our key products is less than we had expected and then because of the turnover in the Santarus sales force, wholesaler discounts higher than budgeted and higher-than-expected rebates on the Santarus products." 
Timothy Creech - SVP, Finance and Administration, and Acting CFO, Q3 2014 earnings call
Going forward, what should investors focus on? We have the pending audit committee review, and this statement:
"...management believes that the company's accounting in relation to sales to wholesalers has been appropriate, and that any questions related to that have all been vetted. Our auditor, Ernst & Young, has conducted its quarterly reviews for each of the 3 quarters. They've also informed us that they stand by their unqualified opinion in respect to their 2013 audited financial statements."
Carolyn J. Logan - Chief Executive Officer, President and Director, Q3 2014 earnings call
This does not mean there will be no revisions to prior period financials, it does mean E&Y does not expect the revisions to be material in nature. While management has tried its best to assure there are no other issues, investors are applying the "one cockroach in the kitchen rule" and staying away. I missed the drop in Salix due to my focus on smaller firms. I currently have no position, but that may change, pending my research below.

In the next post, I will be exploring metrics that may be used to identify earnings manipulators, in the attempt to determine what other revelations Salix investors should expect from the audit committee, if any. 
0 Comments
    Picture
    This is the personal blog of Emory Redd.

    This blog is not investment advice. This is not a solicitation to invest. Don't take candy from strangers.
    Follow @Emory_R
    View my profile on LinkedIn
    BEST OF HEDGEROLL
    ACHILLION AND RA CAPITAL: MY FAVORITE TRADE

    SALIX INVESTORS LOOKING FOR A BUYOUT SHOULD BE CAUTIOUS; MORE ACCOUNTING PROBLEMS AHEAD

    BIOTECH AS BUFFETT'S WONDERFUL BUSINESS
    Get Email Updates

    Categories

    All
    13D
    13F
    13G
    Abingworth
    Accounting
    Accounting Fraud
    Achillion ACHN
    Activist
    AGN
    Aig
    Alphasimplex Group
    American Express
    Andrew Lo
    ANTH
    Anthera Pharmaceuticals
    Anthony Scaramucci
    Arbitrage
    ARC-520
    Argonaut Capital Management
    Arrowhead Research
    Artemis
    ARWR
    ASH 2014
    Avenue Capital
    AXP
    Baker Bros. Advisors
    Baker Brothers
    Barton Biggs
    Baupost Group
    BB Biotech
    Bear Stearns
    Beneish M-Score
    BenjaminJGarber.com
    Bershire Hathaway
    Bill Gross
    Biotech Hedge Fund
    Biotechnology
    Biotech Trader Handbook
    Biotech Valuation
    Black Swan
    BMY
    Bob Treue
    Bonds
    Books
    Broadfin Capital
    Bruce Greenwald
    Bubble
    Capital Returns Management
    Carl Icahn
    Carlos Slim
    Carnegie Mellon
    Celgene (CELG)
    Channel-stuffing
    Charlie Munger
    China
    Chris Levett
    Circle-of-competence
    Clive Capital
    Coca-Cola Company
    Coke KO
    Columbia Business School
    Commodities
    Contrarian Trades
    Credit
    Credit Bubble
    Cta
    Currency
    Daniel Gold
    Data Mining
    David Einhorn
    David Gerstenhaber
    David Harding
    David Tepper
    Davita Inc
    D.E. Shaw
    Deutsche Bank
    Donald Trump
    Dunn & Bradstreet DNB
    Dva
    Earnings Manipulation
    Eric Sprott
    Fabozzi-books
    Fed Day
    Federated Investors
    Fees
    Fig
    Fixed Income
    Form 4
    Fortress Investment Group Llc
    Fund Of Funds
    Gartmore
    GILD
    Gilead
    Glaxosmithkline
    Global Macro
    Gold
    Goldman Sachs
    Gotham Capital
    GSK
    HBV
    HCV
    Hedge Fund Start-up
    Hepatitis B
    Hepatitis C
    HIV
    Humor
    IBM
    IgA Nephropathy
    Inflation
    Insurance Companies
    Intellectual Property
    International Business Machines
    Izzy Englander
    Jeffrey Ubben
    JNJ
    Joel Greenblatt
    John Paulson
    Johnson & Johnson
    John W Henry
    Julian Robertson
    Kkr
    KO
    Leon Cooperman
    Loeb
    Long Term Capital Management
    Lupus
    M&A
    Man Group
    Marc Lasry
    Mellon
    Michael Bloomberg
    Michael Burry
    Michael Lewis
    Michael L Roirdan
    Michael Novogratz
    Michael Steinhardt
    Millennium Partners
    Moody's MCO
    Mr. T
    MRX
    Municipal Bonds
    Music
    Nassim Taleb
    Obama
    Occupy Wall Street
    Oil
    Omega Advisors
    Oncology
    Orbimed Advisors
    Orphan Disease
    Palo Alto Investors
    Paul Tudor Jones Iii
    Perceptive Advisors
    Pershing Square
    PG
    Pharmacyclics (PCYC)
    Phil Falcone
    Point State Capital
    Private Equity
    Procter & Gamble
    Quantitative Easing
    Quants
    QVT Financial
    RA Capital
    Redmile Group
    Return On Invested Capital
    Rob Bobman
    Robert Shiller
    Rob Goldstein
    ROIC
    Salix Pharmaceuticals SLXP
    Sanofi-Aventis
    Sebastian Mallaby
    Sec
    Seeding
    Seth Klarman
    Shorts
    Short Selling
    Short Selling Books
    Silver
    Skybridge
    SLXP
    SNY
    Stanley Druckenmiller
    Statistical Arbitrage
    St Joe Company
    Sub-Prime
    Ted Weschler
    The Barnegat Fund
    Thomas Mellon
    Traxis Partners
    Twitter
    Twitter Hedge Fund
    Valeant
    ValueAct
    Value Investing
    Vanderbilt
    VHCP Management
    Victor Niederhoffer
    VRX
    Warren Buffett
    Warren Buffett Letters
    Wells Fargo
    Wfc
    When Stocks Crash Nicely
    William Ackman
    Winton Capital Management
    Wonderful Business
    Yale University

    Archives

    December 2016
    August 2016
    June 2016
    May 2016
    April 2016
    March 2016
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    December 2014
    November 2014
    October 2014
    August 2014
    April 2014
    August 2013
    October 2012
    September 2012
    May 2012
    April 2012
    March 2012
    February 2012
    January 2012
    December 2011
    November 2011
    October 2011
    September 2011
    August 2011
    July 2011
    June 2011
    May 2011
    April 2011
    March 2011
    February 2011
    January 2011
    December 2010
    November 2010
    October 2010
    September 2010

    RSS Feed

Powered by Create your own unique website with customizable templates.
  • HedgeRoll
  • Contact
  • Research